Duracillin A-S
(Penicillin)Phase 3Small molecule
SanofiThis antibiotic injection is used to treat bacterial infections by killing the bacteria that cause them. It is administered as an injection into the muscles and is not effective against viral infections like colds or flu.[1] Duracillin A-S is currently being investigated across 2 indications[3], with its most advanced program in Phase 3.[1]
Duracillin A-S is one of 53 small molecule programs targeting Sickle Cell Disease. It is currently in Phase 3.
2
Indications
6
Total Trials
2
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
272 competitors in Sickle Cell Disease
#DrugCompanyPhaseTrials
1Adakveo
NovartisPhase 3
Exjade
NovartisPhase 3
Brilinta
AstraZenecaPhase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Ritalin
NovartisPhase 3
Cysteine Hydrochloride
NovartisPhase 3
Eliquis
Bristol-Myers SquibbPhase 3
Oxbryta
GGlobal Blood Therapeutics
Phase 3
Aqvesme
AAgios Pharmaceuticals, Inc.
Phase 3
Effient
CCosette Pharmaceuticals, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tonsillitis2 trials
Breastfeeding1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Penicillin. EMBL-EBI & Wellcome Sanger Institute.
- [4]